Truist Financial
SRPT icon

Truist Financial’s Sarepta Therapeutics SRPT Stock Holding History

Truist Financial’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19,200
Closed -$413K – 2905
2025
Q4 		$413K Buy
19,200
+3,500
+22% +$73.8K ﹤0.01% 2149
2025
Q3 		$303K Buy
+15,700
New +$280K ﹤0.01% 2306

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Truist Financial's SRPT Position: Q2 2026 in Review

Truist Financial increased its Sarepta Therapeutics (SRPT) stake by 23% in Q2 2026, buying an estimated $60.7K and bringing the position to 17,030 shares worth $306K. The position accounts for ﹤0.01% of the portfolio, ranked #2529.

Truist Financial first reported a position in SRPT in Q2 2018 and has held it in 24 quarters since. The position peaked at $1.81M in Q3 2020. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Truist Financial held 17,030 shares of Sarepta Therapeutics worth $306K as of Q2 2026.
  • Truist Financial bought 3,208 Sarepta Therapeutics shares in Q2 2026, an estimated $60.7K.
  • Sarepta Therapeutics made up ﹤0.01% of Truist Financial's portfolio in Q2 2026, its #2529 holding.
  • Truist Financial first reported a position in Sarepta Therapeutics in Q2 2018 and has held it in 24 quarters since.
  • Truist Financial's Sarepta Therapeutics position peaked at $1.81M in Q3 2020.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Truist Financial's 13F filing for Q2 2026, filed 28 Jul 2026.